공간 단백질체학 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 워크플로우별, 샘플 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Spatial Proteomics Market Growth & Trends:

The global spatial proteomics market size is expected to reach USD 199.8 million by 2030, registering a CAGR of 15.06% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing demand for precision medicine and personalized therapies, particularly in oncology. As cancer continues to be one of the leading causes of death worldwide, as per NIH cancer statistics, over 1.9 million new cases were reported in the U.S. in 2023. There is a growing need for advanced technologies that can provide detailed insights into tumor biology and the tumor microenvironment. The growing focus on personalized medicine, advancements in genomics and proteomics, and rising investments in cancer research are key factors fueling the market growth of spatial proteomics over the forecast period.

In addition, spatial proteomics offers a unique advantage by allowing researchers to visualize protein interactions in their native tissue context, enabling the identification of specific biomarkers and therapeutic targets. This technology's ability to dissect cellular heterogeneity and understand disease mechanisms at a deeper level has led to its adoption in research and drug development, especially for complex diseases like cancer, thus boosting market growth.

Another key driver of the market is the growing investment in proteomics research from both government agencies and private sectors. The aging population and the rising prevalence of chronic diseases, such as cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases, have increased the demand for innovative diagnostic and therapeutic solutions. According to the World Health Organization (WHO), the proportion of people aged 60 years and older is expected to reach 2.1 billion by 2050, driving the need for more advanced technologies like spatial proteomics to develop effective treatments tailored to this patient population. This surge in funding and collaborative efforts between pharmaceutical companies, biotech firms, and academic institutions has accelerated technological advancements and expanded the application of spatial proteomics in various fields beyond oncology.

However, the market faces significant restraints, one of which is the high cost of advanced imaging and mass spectrometry equipment. These instruments require substantial capital investment, making them less accessible to smaller research institutions and laboratories with limited budgets.

Spatial Proteomics Market Report Highlights:

• Based on product, consumables for spatial proteomics accounted for the largest revenue share of 56.19% in 2024.
• Based on technology, imaging-based technologies for spatial proteomics accounted for the largest revenue share of 36.92% in 2024.
• Based on workflow, the instrumental analysis accounted for the largest revenue share of 47.2% in 2024.
• Based on sample type, the FFPE accounted for the largest revenue share of 58.53% in 2024. The FFPE samples are extensively used in hospitals, biobanks, and research institutions, containing vast collections of archived tissues from diverse patient populations, disease states, and time periods.
• Based on end-use, the academic & translational research institutes segment accounted for the largest revenue share of 67.92% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
• North America spatial proteomics market dominated the global market in 2024 with a share of 49.13%. This is attributed to advanced healthcare infrastructure, substantial investment in research and development (R&D), and the presence of key market players.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product Segment
  • 1.1.2. Technology Segment
  • 1.1.3. Workflow Segment
  • 1.1.4. Sample Type Segment
  • 1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Demand for Precision Medicine and Personalized Therapies
    • 3.2.1.2. Increasing Investment and Funding in Proteomics Research
    • 3.2.1.3. Rising incidence of cancer
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Advanced Spatial Proteomics Technologies
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Spatial proteomics market Product Movement Analysis
• 4.3. Spatial proteomics market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Automated
    • 4.4.2.1. Automated market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Semi-automated & Manual
    • 4.4.3.1. Semi-automated & manual market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Software
  • 4.6.1. Software market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Technology Group Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Spatial proteomics market Technology Movement Analysis
• 5.3. Spatial proteomics market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. Imaging-based Technologies
  • 5.4.1. Imaging-based technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Mass Spectrometry-based Technologies
  • 5.5.1. Mass spectrometry-based technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Sequencing-based Technologies
  • 5.6.1. Sequencing-based technologies market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Other technologies
  • 5.7.1. Other technologies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Workflow Group Business Analysis

• 6.1. Workflow Segment Dashboard
• 6.2. Spatial proteomics market Workflow Movement Analysis
• 6.3. Spatial proteomics market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 6.4. Sample Preparation
  • 6.4.1. Sample preparation market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Instrumental Analysis
  • 6.5.1. Instrumental analysis market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Data Analysis
  • 6.6.1. Data analysis market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Sample Type Group Business Analysis

• 7.1. Sample Type Segment Dashboard
• 7.2. Spatial proteomics market Sample Type Movement Analysis
• 7.3. Spatial proteomics market Size & Trend Analysis, by Sample Type, 2018 to 2030 (USD Million)
• 7.4. FFPE
  • 7.4.1. FFPE market estimates and forecasts, 2018 - 2030 (USD Million)
• 7.5. Fresh Frozen
  • 7.5.1. Fresh frozen market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Spatial proteomics market End Use Movement Analysis
• 8.3. Spatial proteomics market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Academic & Translational Research Institutes
  • 8.4.1. Academic & translational research institute market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Pharmaceutical and Biotechnology Companies
  • 8.5.1. Pharmaceutical and biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. Other End Use
  • 8.6.1. Other end use market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis by Product, Technology, Workflow, Sample Type, End Use

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
• 9.3. North America
  • 9.3.1. North America Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Spatial proteomics market, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Denmark Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Spatial proteomics market, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Japan Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. China Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Australia Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Thailand Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. South Korea Spatial proteomics market, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Spatial proteomics market, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Saudi Arabia Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. UAE Spatial proteomics market, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Spatial proteomics market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. 10X genomics
    • 10.4.1.1. Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Bruker
    • 10.4.2.1. Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. Fluidigm Corporation
    • 10.4.3.1. Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. NanoString Technologies, Inc.
    • 10.4.4.1. Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. Akoya Biosciences, Inc.
    • 10.4.5.1. Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. PerkinElmer
    • 10.4.6.1. Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Danaher
    • 10.4.7.1. Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Biotechne
    • 10.4.8.1. Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. S2 Genomics, Inc.
    • 10.4.9.1. Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Seven Bridges Genomics Inc.
    • 10.4.10.1. Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives